Literature DB >> 8139215

Immature teratoma of the uterine fundus.

S Iwanaga1, A Shimada, Y Hasuo, S Yoh, S Miyajima, H Nishimura, M Yakushiji.   

Abstract

An exceedingly rare case of extragonadal immature teratoma, which occurred primarily in the uterus, is described. The tumor developed into the pelvic cavity from the uterine fundus and consisted of ectodermal, mesodermal and endodermal derivatives. There were also significant amounts of immature elements; immature neuroepithelium with brisk mitotic activity, immature mesenchymal tissue, immature cartilage, immature striated muscle and immature hepatic tissue. Histologically, it was classified as a grade 3 immature teratoma. Treatment consisted of total simple hysterectomy followed by 2 courses of combination chemotherapy with vincristine, actinomycin D and cyclophosphamide (VAC). The patient was well and without evidence of recurrence at 5 years post-operatively.

Entities:  

Mesh:

Year:  1993        PMID: 8139215     DOI: 10.2739/kurumemedj.40.153

Source DB:  PubMed          Journal:  Kurume Med J        ISSN: 0023-5679


  3 in total

1.  Immature uterine teratoma associated with uterine inversion.

Authors:  Karla Teixeira Souza; Marcelo Vailati Negrão; Lucila Soares da Silva Rocha; Giovanni Di Favero; Samantha Cabral Severino da Costa; Maria Del Pilar Estevez Diz
Journal:  Rare Tumors       Date:  2014-08-12

2.  Primary immature teratoma of the uterus relapsing as malignant neuroepithelioma: case report and review of the literature.

Authors:  Meryam Ben Ameur El Youbi; Amina Mohtaram; Jinane Kharmoum; Imane Aaribi; Saoussane Kharmoum; Abdelilah Bouzoubaa; Hind M'rabti; Saber Boutayeb; Basma El Khannoussi; Hassan Errihani
Journal:  Case Rep Oncol Med       Date:  2013-06-04

3.  Case report: malignant teratoma of the uterine corpus.

Authors:  Thomas Newsom-Davis; Daniel Poulter; Rebecca Gray; Mohammed Ameen; Iain Lindsay; Kyriakos Papanikolaou; Simon Butler-Manuel; Timothy Christmas; Peter Townsend; Michael Seckl
Journal:  BMC Cancer       Date:  2009-06-18       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.